Forward looking statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company’s financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial guidance is provided under the investor section of Myriad’s corporate website.
Our purpose-driven mission to transform and improve lives is more relevant than ever.

We have a strong, compelling market opportunity as a leader in genetics and molecular diagnostics.

But the market is changing faster than we are.

We must transform to win, put patients and customers first, reset our base, simplify our business, and drive new commercial capabilities.

The new Myriad Genetics will create new growth opportunities for us all.

Paul J. Diaz
President and CEO
Advancing our mission in large and growing markets

<table>
<thead>
<tr>
<th>Women’s Health</th>
<th>Oncology</th>
<th>Mental Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>166M women in U.S.</td>
<td>1.7M new patients diagnosed annually with 15M affected</td>
<td>&gt;11M new patients diagnosed annually with &gt;40M affected</td>
</tr>
<tr>
<td>Demand for services growing 6% per year</td>
<td>$137B in U.S. healthcare spending</td>
<td>$201B in U.S. healthcare spending</td>
</tr>
<tr>
<td>Most active and engaged group in seeking information and stewardship of family healthcare</td>
<td>&gt;$40B drug spend 40% response</td>
<td>&gt;$60B drug spend, 48% response</td>
</tr>
<tr>
<td></td>
<td>600,000 U.S. deaths per year</td>
<td>800,000 deaths in U.S. annually</td>
</tr>
</tbody>
</table>
A Powerful Thesis for Transformation

- Large, growing market opportunity - $10B+
- Economics of molecular diagnostics support sustainable, profitable growth
- Respected portfolio, scientific know-how and reach
- Opportunities to elevate our products to full potential
- Need to reset our competitive and financial position by reducing complexity and cost
- Winning culture, strong leadership team, and record of innovation are the foundation for delivering on our mission, market leadership, long-term growth and profitability
Transformation phases and objectives

H2 2020

- Continue COVID volume recovery and execute on near-term opportunities
- Prioritize product innovation, research and technology initiatives
- Establish firm financial position, reduce complexity and cost
- Define and deploy winning, customer-centric, technology-enabled commercial model
- Develop and launch comprehensive transformation plan

2021

- Reorganize around strategic priorities, reduce complexity and cost
- Improve financial performance and transparency with investors
- Enhance reimbursement and revenue cycle capabilities

2022

- Invest in innovation, research and partnerships to accelerate organic growth
- Build commercial capabilities to support new products and potential M&A

PHASE I: RESET THE BASE

PHASE II: REFOCUS ORGANIZATION

PHASE III: REIGNITE GROWTH
Four-point strategic roadmap

1. Put patients and customers first
   - Convey our unique value proposition
   - Play offense with price positioning and reimbursement
   - Ramp up consumer and digital marketing
   - Enable frontline and virtual sales with best-in-class training and support

2. Build new commercial capabilities
   - Increase awareness and access
   - Bolster differentiation with messaging and innovation
   - Reinforce clinical utility
   - Maximize cross-sell and synergies across the portfolio

3. Elevate core products to full potential
   - Increase awareness and access
   - Bolster differentiation with messaging and innovation
   - Reinforce clinical utility
   - Maximize cross-sell and synergies across the portfolio

4. Create new avenues of growth
   - Explore and assess
   - Direct-to-Consumer marketing models, new partnerships, dataset monetization
Better serving patients and providers – IT enabled

- **Education**
  - MyGeneHistory - Risk assessment at home or in clinic, EMR integration, AI-driven guides, Personalized workflow

- **Telehealth**
  - 30% of GeneSight sample kits shipped direct to patients, Tele-Psychiatry partnerships

- **Access**
  - Transparent, personalized out of pocket cost estimates. Phlebotomy finder and at-home visits

- **Portal**
  - Patient and provider portals for results delivery and order management.
    - 30% reduction in time per order
    - EMR scale-out to 275+ new interfaces
Driving digital engagement and conversion

Hereditary Cancer Quiz
Driving follow through

Patient Interest
Quiz Completions
Criteria Qualifications
Checking on Next Steps
Lead
Order
Sample Submissions

GROWTH OPPORTUNITY
2.8% who take quiz and meet national (NCCN) criteria convert to complete myRisk tests.
September 2020 Quarter - sequential volume increases

Significant recovery in test volume

<table>
<thead>
<tr>
<th>Product</th>
<th>Sequential Increase in Test Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary Cancer</td>
<td>78%</td>
</tr>
<tr>
<td>GeneSight</td>
<td>61%</td>
</tr>
<tr>
<td>Prequel</td>
<td>5%</td>
</tr>
<tr>
<td>ForeSight</td>
<td>14%</td>
</tr>
<tr>
<td>Vectra</td>
<td>53%</td>
</tr>
<tr>
<td>Prolaris</td>
<td>30%</td>
</tr>
<tr>
<td><strong>Total Test Volume</strong></td>
<td><strong>40%</strong></td>
</tr>
</tbody>
</table>
### September 2020 Quarter - revenue by product

#### Three Months Ended September 30

<table>
<thead>
<tr>
<th></th>
<th>2020 (in millions)</th>
<th>2019 (in millions)</th>
<th>% Change</th>
<th>Change</th>
<th>ASP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WH</td>
<td>ONC</td>
<td>MH</td>
<td>AI</td>
<td>Other</td>
</tr>
<tr>
<td>Molecular diagnostic testing revenue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hereditary Cancer</td>
<td>$39.2</td>
<td>$41.4</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>GeneSight®</td>
<td>-</td>
<td>-</td>
<td>11.9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Prenatal</td>
<td>16.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vectra®</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9.1</td>
<td>-</td>
</tr>
<tr>
<td>Prolaris®</td>
<td>-</td>
<td>6.4</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>EndoPredict®</td>
<td>-</td>
<td>2.8</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>myChoice® CDx</td>
<td>-</td>
<td>7.8</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other testing revenue</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.6</td>
</tr>
<tr>
<td>Total molecular diagnostic testing revenue</td>
<td>55.7</td>
<td>58.4</td>
<td>11.9</td>
<td>9.1</td>
<td>0.6</td>
</tr>
<tr>
<td>Pharmaceutical and clinical service revenue</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9.5</td>
</tr>
<tr>
<td>Total Revenue</td>
<td>$55.7</td>
<td>$58.4</td>
<td>$11.9</td>
<td>$9.1</td>
<td>$10.1</td>
</tr>
</tbody>
</table>

**WH = Women’s Health**  
**ONC = Oncology**  
**MH = Mental Health**  
**AI = Autoimmune**
# September 2020 Quarter - income statement

## Myriad Genetics Income Statement

<table>
<thead>
<tr>
<th>GAAP Results</th>
<th>Adjusted Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sep-20</td>
<td>Sep-20</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td>$145.2</td>
</tr>
<tr>
<td>Cost of Goods Sold</td>
<td>44.2</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>101.0</td>
</tr>
</tbody>
</table>

### Operating Expenses
- Research and Development | 17.6 | 16.1 |
- Selling, General, and Administrative | 124.1 | 97.3 |
- Contingent Consideration | (1.1) | 0.0 |

**Total Operating Expenses** | 140.6 | 113.4 |

### Operating Income
- (39.6) | (12.1) |

### Other Income/Expense
- Interest Income/Expense | (2.5) | (2.5) |
- Other | (1.6) | (0.1) |

**Total Other Income** | (4.1) | (2.6) |

### Income Before Taxes
- (43.7) | (14.7) |

### Tax Expense / (Break)
- (28.5) | (3.4) |

**Net Income / (Loss)** | ($15.2) | ($11.3) |

**Net income attributable to MYGN stockholders** | ($15.2) | ($11.3) |

**Fully Taxed Reported/Adjusted EPS** | ($0.20) | ($0.15) |

**Diluted Shares Outstanding** | 74.7 | 74.7 |
Reducing expenses, reinvesting in growth

$40M ANNUALIZED SAVINGS

$20M STRATEGIC INVESTMENTS
Accelerating momentum

Recent Wins

- American College of Obstetricians & Gynecologists - average risk non-invasive pre-natal screening
- AMPLIFY™ launch
- BCBS Evidence Street assessment

Women’s Health

Near-Term Opportunities

- Direct to consumer marketing initiatives
- Hereditary Cancer Quiz patient conversion

Oncology

- German Federal Joint Committee (G-BA) EndoPredict coverage
- Expanded coverage for Prolaris – 25% test volume

Mental Health

- GeneSight Local Coverage Determination (LCD) expands coverage
- Broadened GeneSight access for primary care providers
- Japan, China, Europe opportunities for myChoice CDX

- Reduce zero-pays
- Payer collaborations
- Telehealth partnerships
Corporate governance improvements

Board Refresh

2/3 of board members new at end of Dec. annual meeting
44% of board members from diverse backgrounds
Moved from plurality to majority voting for directors

Executive Compensation

Aligned to performance, shareholder interests
70% of bonus payout for VP and above tied to revenue and operating income
Equity granted as long-term incentive comp consists of 50% performance shares - # of shares tied to EPS and shareholder return
Reduced management payouts under a change-of-control
Eliminated future cash long-term incentive programs

Calendar Year

Moved from fiscal to calendar year
January through December
Unlocking the power of genetics to improve and transform lives